¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"cytotoxic T lymphocyte"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 2 ÆäÀÌÁö: 1
¿µ¹® lymphocyte ÇÑ±Û ¸²ÇÁ±¸
¼³¸í   
  ¸é¿ª±â´ÉÀ» ´ã´çÇϴ ¼¼Æ÷. °ñ¼ö¿¡¼­ ¸¸µé¾îÁö¸ç, ¸²ÇÁ±¸´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷, B¸²ÇÁ¼¼Æ÷·Î ³ª´µ¾îÁö°Ô µÈ´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â(¸é¿ª¹ÝÀÀ 4¹øÇü µî) µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ°¨¿°¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ» ´ã´çÇÑ´Ù.
¿µ¹® T-lymphocyte ÇÑ±Û Æ¼ ¸²ÇÁ±¸
¼³¸í   
  ¸²ÇÁ°è¼¼Æ÷(¸²ÇÁ±¸)´Â Å©°Ô 2°¡Áö·Î ´ëºÐµÈ´Ù. À̸¥¹Ù T¸²ÇÁ¼¼Æ÷(T-cell), B¸²ÇÁ¼¼Æ÷(B-cell)·Î ³ª´µ¾îÁø´Ù. T¸²ÇÁ¼¼Æ÷´Â ¼¼Æ÷¼º ¸é¿ª¿¡ °ü¿©Çϸç, ÁַΠ¹ÙÀÌ·¯½ºº´¿¡ ´ëÇÑ ¸é¿ª±â´ÉÀ̳ª, ¾Ë·¹¸£±â µî¿¡ °ü¿©ÇÑ´Ù. ÀÌ¿¡ ºñÇØ B¸²ÇÁ¼¼Æ÷´Â Ã¼¾×¼º ¸é¿ª¿¡ °ü¿©ÇÏ¿©, Ç׿ø Ç×ü ¹ÝÀÀÀ» ÀÏÀ¸Å°´Â Ç×ü¸¦ »ý»êÇϰí ÁַΠ¼¼±Õ¼º Áúȯ¿¡ ´ëÇÑ ¸é¿ª ±â´ÉÀ» ´ã´çÇÑ´Ù. T-¸²ÇÁ±¸´Â ¸é¿ª±â´É¿¡ °¡Àå Áß¿äÇÑ ¿ªÇÒÀ» Çϴ ¼¼Æ÷·Î¼­ ¼¼Æ÷¸é¿ªÀ» ´ã´çÇϸç B-cellÀÇ ÀÛ¿ëÀ» Á¶ÀýÇϴ ±â´Éµµ ÀÖ´Ù. °ñ¼ö¿¡¼­ »ý¼ºµÇ¾î °¡½¿»ù¿¡¼­ ¼º¼÷µÈ´Ù. Å©°Ô º¸Á¶T¼¼Æ÷(helper T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» º¸Á¶ÇÑ´Ù)¿Í T¼¼Æ÷(suppressor T-cell: ¸é¿ªÀÛ¿ëÀÇ ¹ß»ýÀ» ¾ïÁ¦ÇÑ´Ù)·Î ±¸ºÐµÇ¸ç À̵éÀº ¼¼Æ÷ Ç¥¸é¿¡ ºÐÆ÷Çϴ Ç׿ø¿¡ ÀÇÇØ¼­ ½Äº°µÉ ¼ö ÀÖ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic
    ¼¼Æ÷µ¶¼º-
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹éÁú
  • cytotoxic chemotherapy
    ¼¼Æ÷µ¶¼ºÈ­Çпä¹ý
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • cytotoxic edema
    ¼¼Æ÷µ¶¼ººÎÁ¾
  • cytotoxic hypersensitivity
    ¼¼Æ÷µ¶¼º°ú¹Î¼º
  • cytotoxic hypoxia
    ¼¼Æ÷µ¶¼ºÀú»ê¼ÒÁõ
  • cytotoxic killer T cell
    ¼¼Æ÷µ¶¼º»ìÇØT¼¼Æ÷
  • cytotoxic reaction
    ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • atypical lymphocyte
    ºñÁ¤Çü¸²ÇÁ±¸
  • effector lymphocyte
    È¿°ú¸²ÇÁ±¸
  • killer lymphocyte
    »ìÇØ¸²ÇÁ±¸, ¼¼Æ÷µ¶¼º¸²ÇÁ±¸
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic chemotherapy
    Ç×¾ÏÈ­Çпä¹ý
  • mixed lymphocyte culture
    È¥ÇÕ¸²ÇÁ±¸¹è¾ç
  • lymphocyte
    ¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic agent
    ¼¼Æ÷µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic
    ¼¼Æ÷µ¶¼º-
  • cytotoxic cell
    ¼¼Æ÷µ¶¼º¼¼Æ÷
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°
  • cytotoxic edema
    ¼¼Æ÷µ¶¼ººÎÁ¾
  • cytotoxic hypersensitivity
    ¼¼Æ÷µ¶¼º°ú¹Î
  • cytotoxic hypoxia
    ¼¼Æ÷µ¶¼ºÀú»ê¼ÒÁõ
  • cytotoxic reaction
    µ¶¼º¹ÝÀÀ, ¼¼Æ÷µ¶¼º¹ÝÀÀ
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º¼¼Æ÷´Ü¹é
  • atypical lymphocyte
    ºñÀüÇü¸²ÇÁ±¸
  • lymphocyte-activating determinant
    ¸²ÇÁ±¸È°¼º°áÁ¤±â
  • effector lymphocyte
    ÀÛµ¿¸²ÇÁ±¸
  • lymphocyte activating factor
    ¸²ÇÁ±¸È°¼ºÀÎÀÚ
  • lymphocyte inhibitory factor
    ¸²ÇÁ±¸¾ïÁ¦ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • T cell ; T lymphocyte ; thymus derived lymphocyte
    T¼¼Æ÷ ; T¸²ÇÁ? ; Èä¼±À¯·¡¸²ÇÁ?
  • Cytotoxic
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ)
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • B cell/lymphocyte
    B ¼¼Æ÷/¸²ÇÁ±¸
  • B lymphocyte
    B ¸²ÇÁ±¸
  • B-lymphocyte
    B ¸²ÇÁ±¸.
  • Bare lymphocyte syndrome
    ¹«Ç¥Áö¸²ÇÁ±¸ÁõÈıº
  • T cell/lymphocyte
    T ¼¼Æ÷/¸²ÇÁ±¸
  • T lymphocyte
    T ¸²ÇÁ±¸
  • T-lymphocyte
    T-Àӯı¸
  • anti-lymphocyte globulin
    ¸²ÇÁ±¸ Çױ۷κҸ°
  • antigen, lymphocyte defined (LD)
    ¸²ÇÁ±¸ Ç¥¸éÇ׿ø, LDÇ׿ø
  • granulocyte-monocyte-lymphocyte antigens
    °ú¸³±¸´Ü±¸¸²ÇÁ±¸Ç׿ø
  • granulocyte-platelet-lymphocyte antigens
    °ú¸³±¸Ç÷¼ÒÆÇ¸²ÇÁ±¸Ç׿ø
  • hodgkins disease,lymphocyte predominance
    ¸²ÇÁ±¸ ÇöÀúÇü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic T lymphocyte (CTL)
    ¼¼Æ÷µ¶¼ºT¸²ÇÁ±¸
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • antibody, cytotoxic
    ¼¼Æ÷µ¶¼ºÇ×ü
  • cytotoxic
    <¾à¹°>, ¼¼Æ÷µ¶¼º(¡­Ô¸àõ)ÀÇ.
  • cytotoxic
    ¼¼Æ÷µ¶¼º(¡­Ô¸àõ)ÀÇ.
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º T ¼¼Æ÷
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼ºT¼¼Æ÷
  • cytotoxic T-cell ; killer T-cell
    (¼¼Æ÷)»ì(ÇØ) T¼¼Æ÷.
  • cytotoxic action
    ¼¼Æ÷µ¶ÀÛ¿ë.
  • cytotoxic agent
    ¼¼Æ÷ µ¶¼ºÁ¦
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼ºÇ×ü.
  • cytotoxic antibody
    °ú¼¼Æ÷µ¶Ç×ü, ¼¼Æ÷µ¶¼ºÇ×ü.
  • cytotoxic antitumor antibody
    ¼¼Æ÷µ¶¼ºÇ×Á¾¾çÇ×ü
  • cytotoxic cell protein
    ¼¼Æ÷µ¶¼º ¼¼Æ÷´Ü¹é
  • cytotoxic drug
    ¼¼Æ÷µ¶¼º¾à¹°.
  • cytotoxic drug
    Ç÷¾×Æ÷µ¶¼ºÁ¦<¾à>, ¼¼Æ÷µ¶¼º ¾à¹°.
  • cytotoxic effect
    ¼¼Æ÷µ¶¼ºÈ¿°ú
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • Small lymphocyte
    ÀÛÀº¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ¼ÒÀӯı¸
  • Large lymphocyte
    Å«¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ´ëÀӯı¸
  • Medium-sized lymphocyte
    Áß°£¸²ÇÁ±¸
    [¿¾ ¿ë¾î] ÁßÀӯı¸
  • Lymphocyte
    ¸²ÇÁ±¸
    [¿¾ ¿ë¾î] Àӯı¸
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic anaphylaxis
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) ¾Æ³ªÇʶô½Ã½º
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼º Ç×ü(á¬øàÔ¸àõù÷ô÷)
  • cytotoxic T cell
    ¼¼Æ÷µ¶¼º(á¬øàÔ¸àõ) T ¼¼Æ÷(á¬øà)
  • lymphocyte-derived chemotactic factor
    ¸²ÇÁ±¸-À¯µµ(ë¯Óô) È­ÇÐÁÖ¼ºÀÎÀÚ(ûùùÊñËà÷ì×í­)
  • lymphocyte transformation
    ¸²ÇÁ±¸º¯Çü(ܨû¡)
  • mixed lymphocyte culture
    È¥ÇÕ(ûèùê)¸²ÆÄ±¸¹è¾ç(ÛÆå×)
  • small lymphocyte
    ¼Ò(á³)Àӯı¸
  • T lymphocyte
    T Àӯı¸
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • cytotoxic
    ¼¼Æ÷µ¶¼º ¹°Áú, ¼¼Æ÷µ¶¼ºÀÇ
  • lymphocyte
    ¸²ÇÁ±¸
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • T lymphocyte
    T¸²ÇÁ±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CTL cervico-thoraco-lumbar; control; cytolytic C lymphocyte; cytotoxic T-lymphocyte
CL capillary lumen; cardiolipin; cell line; centralis lateralis; chemiluminescence; chest and left arm ...
CLMF cytotoxic lymphocyte maturation factor
HLA-LD human lymphocyte antigen-lymphocyte defined
LD labor and delivery; laboratory data; labyrinthine defect; lactate dehydrogenase; laser Doppler; lear...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
CTLA-4 Cytotoxic T Lymphocyte Antigen-4
CTLA-4 Cytotoxic T lymphocyte associated antigen 4
CTLp Cytotoxic T lymphocyte precursor
CLP cytotoxic T lymphocyte precursors
ADCC Antibody dependent cellular cytotoxic
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • cytotoxic
    ¼¼Æ÷ µ¶¼º
    ¼¼Æ÷ µ¶¼Ò¿¡ ÀÇÇÑ. ¼¼Æ÷ µ¶ ÀÛ¿ëÀ» Áö´Ñ.
  • cytotoxic antibody
    ¼¼Æ÷ µ¶ Ç×ü, ¼¼Æ÷ µ¶¼º Ç×ü
  • cytotoxic factor
    ¼¼Æ÷ µ¶¼º ÀÎÀÚ
  • cytotoxic substance
    ¼¼Æ÷ µ¶, ¼¼Æ÷µ¶¼Ò
    µ¿ÀǾî=cytotoxin.
  • humoral cytotoxic antibody
    ü¾×¼º ¼¼Æ÷ µ¶¼º Ç×ü
  • T cell cytotoxic
    T ¼¼Æ÷ µ¶¼º
  • B lymphocyte
    B ¸²ÇÁ±¸
    1. Èä¼± ºñÀÇÁ¸¼ºÀ¸·Î Èä¼±ÀÇ ¿µÇâÀ» ¹ÞÁö ¾Ê°í, Á¶Á÷À» À¯ÁÖÇÏ´Â ¸²ÇÁ±¸. ü¾×¼º ¸é¿ª¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϸç, Ç׿ø¿¡ ÀÇÇÑ ÀÚ±ØÀ¸·Î ¾×¼º Ç×ü¸¦ ÇÕ¼ºÇÏ´Â ÇüÁú±¸·Î µÈ´Ù. 2. Ç÷¾×, °ñ¼ö ¹× ¸²ÇÁÀý, ºñÀå, Æíµµ µî ¸²ÇÁÁ¶Á÷, ±×¸®°í ¼ÒÈ­°ü°è µîÀÇ ºñ¸²ÇÁ Á¶Á÷¿¡ ºÐÆ÷ÇÑ´Ù. ÀÎü Ç÷¾×ÀÇ 10-20% Â÷ÁöÇÑ´Ù. Ç׿ø µî¿¡ ÀÇÇØ Ȱ¼ºÈ­µÇ¸é ¸²ÇÁ¿©Æ÷ ³»¿¡¼­ ¸ð¼¼Æ÷ º¯È¯
  • B-lymphocyte
    B ¸²ÇÁ±¸
    Ç÷Áß Àӯı¸ÀÇ 5-15%¸¦ Â÷ÁöÇÏ¸ç ¼¼Æ÷ Ç¥¸é¿¡ ¸é¿ª ±Û·ÎºÎ¸°ÀÌ Á¸ÀçÇÑ´Ù. ÀÌµé ¸é¿ª ±Û·ÎºÎ¸°Àº Ç׿ø¿¡ ´ëÇÑ ¼ö¿ëü·Î ÀÛ¿ëÇÑ´Ù. Ç÷Áß B ¼¼Æ÷ÀÇ ´ëºÎºÐÀº Ç¥¸é¿¡ IgM°ú IgD¸¦ °®°í ÀÖÀ¸¸ç ¼Ò¼ö¿¡¼­ IgG, IgA ȤÀº IgE°¡ ¹ß°ßµÈ´Ù. ±×·¯³ª Á¡¸· µî¿¡¼­´Â IgA¸¦ °®°í ÀÖ´Â B¼¼Æ÷°¡ ¸¹ÀÌ ¹ß°ßµÈ´Ù.
  • bone marrow-derived lymphocyte
    °ñ¼ö À¯·¡ Àӯı¸
  • bursa-derived lymphocyte
    ÆÄºÎ¸®½Ã¿ì½º ³¶ À¯·¡ Àӯı¸
  • effector lymphocyte
    ÀÛµ¿ ¸²ÇÁ±¸
  • immunocompetent T lymphocyte
    ¸é¿ª Àû°Ý T Àӯı¸
  • lymphocyte
    Àӯı¸
  • lymphocyte defined antigen
    ¸²ÇÁ±¸ ±ÔÁ¤ Ç׿ø
  • lymphocyte migration
    Àӯı¸ À̵¿
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
cytotoxic t-lymphocyte A type of CD8 or, less often, CD4 lymphocyte that kills diseased cells infected by a specific virus or other intracellular microbe. CTLs interact with MHC class I receptors (see Major Histocompatibility Complex). On infected cells and have the prime role in cellmediated immunity (see). Cytovene:
See: Ganciclovir.
(09 Oct 1997)
lymphocyte lymphocyte A type of non-granular antibodies.
(09 Oct 1997)
antireticular cytotoxic serum An antiserum specific for cells of the reticuloendothelial system.
(05 Mar 2000)
cytotoxic <pharmacology> Chemicals that are directly toxic to cells, preventing their reproduction or growth. Cytotoxic agents can, as a side effect, damage healthy, noncancerous tissues or organs which have a high proportion of actively dividing cells, for example, bone marrow, hair follicles. These side effects limit the amount and frequency of drug administration.
(16 Dec 1997)
cytotoxic cell Cells of the immune system that inhibit or help to terminate an immune response, e.g., suppressor macrophages and suppressor T-cells.
Synonym: cytotoxic cell.
(05 Mar 2000)
cytotoxic drugs <pharmacology> Anti-cancer drugs which act by killing or preventing the division of cells.
See: chemotherapy.
(13 Nov 1997)
cytotoxic reaction An immunologic (allergic) reaction in which noncytotropic IgG or IgM antibody combines with specific antigen on cell surfaces; the resulting complex initiates the activation of complement which causes cell lysis or other damage, or which, in the absence of complement, may lead to phagocytosis or may enhance T lymphocyte involvement.
(05 Mar 2000)
cytotoxic T-cell <haematology, immunology> Subset of T lymphocytes (mostly CD8) responsible for lysing target cells and for killing virus infected cells (in the context of Class I histocompatibility antigens).
(18 Nov 1997)
T cytotoxic cells Lymphocyte-like effector cells which mediate antibody-dependent cell cytotoxicity. They kill antibody-coated target cells which they bind with their fc receptors.
(12 Dec 1998)
T-lymphocytes, cytotoxic Immunised T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (mlc), in vivo during a graft-versus-host (gvh) reaction, or after immunization with an allograft, tumour cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (cml). These cells are distinct from natural killer cells (killer cells, natural) and from killer cells mediating antibody-dependent cell cytotoxicity.
(12 Dec 1998)
antigens, differentiation, b-lymphocyte Membrane antigens associated with maturation stages of B-lymphocytes, often expressed in tumours of B-cell origin.
(12 Dec 1998)
antigens, differentiation, t-lymphocyte Antigens expressed on the cell membrane of T-lymphocytes during differentiation, activation, and normal and neoplastic transformation. Their phenotypic characterization is important in differential diagnosis and studies of thymic ontogeny and T-cell function.
(12 Dec 1998)
bare lymphocyte syndrome <syndrome> Absence of HLA antigens on peripheral mononuclear cells, which may result in immunodeficiency.
(05 Mar 2000)
B lymphocyte <haematology, immunology> An immunologically important lymphocyte, produced by the bone marrow, that is responsible for the production of immunoglobulins, it is the precursor of the plasma cell.
The surface markers can be used to detect and differentiate chronic lymphocytic leukaemia from acute lymphocytic leukaemia.
(13 Nov 1997)
b-lymphocyte subsets A classification of B-lymphocytes based on structurally or functionally different populations of cells.
(12 Dec 1998)
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 1 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • lymphocyte
    ¸²ÇÁÅç(¼¼Æ÷)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á